John Marsella, MD
Interventional Pain Medicine · Montgomery, ALNPI 1326027236
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,688 of the $7,677 with a category attached, or 61.1%. 30 manufacturers reported payments, led by Abbott at 48.2% of the total.
Across 192 payments — averaging $39.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- MML US, Inc.$1K
- Boston Scientific$577
- Collegium Pharmaceutical, Inc.$310
- Forte Bio-pharma LLC$240
- Si-bone, Inc.$175
- plus $1K from 24 others
What the payments were for
- Travel & lodging$2,97539%
- Food & beverage$4,68861%
- Entertainment$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 59 | $3,701 |
| MML US, Inc. | 15 | $1,318 |
| Boston Scientific | 28 | $577 |
| Collegium Pharmaceutical, Inc. | 15 | $310 |
| Forte Bio-pharma LLC | 21 | $240 |
| Si-bone, Inc. | 3 | $175 |
| Nevro Corp. | 8 | $168 |
| Medtronic | 4 | $157 |
| Stimwave Technologies Incorporated | 3 | $156 |
| Curonix LLC | 2 | $132 |
| Arbor Pharmaceuticals, Inc. | 5 | $102 |
| Baxter Healthcare | 2 | $79 |
| IBSA Pharma Inc. | 4 | $78 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $54 |
| GRT US Holding, Inc. | 1 | $45 |
| Vertex | 2 | $42 |
| SPR Therapeutics, Inc | 2 | $40 |
| Kls-martin L.p. | 1 | $39 |
| Scilex Pharmaceuticals Inc. | 2 | $36 |
| Flowonix Medical Incorporated | 2 | $36 |
| Nalu Medical, Inc. | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Almatica Pharma LLC | 1 | $21 |
| Globus Medical | 1 | $19 |
| AbbVie | 1 | $17 |
| Biotronik NRO, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Averitas Pharma Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Biodelivery Sciences International, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Proclaim Family of SCS IPGs$1,425
- Proclaim IPG$1,038
- ReActiv8$847
- Axium INS DRG IPG$170
- iFuse Implant$134
- INTELLIS$128
- WaveWriter Alpha Prime 16$105
How this compares
$7,677 in reported general payments places this provider in the 60th percentile of 33 interventional pain medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 19 | $43,012 |
| Buprenorphine | 140 | $42,870 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,563 | $42,534 |
| OxycontinOxycodone Hcl | 48 | $37,931 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,196 | $37,633 |
| Lidocaine | 142 | $13,700 |
| Fentanyl | 119 | $12,255 |
| MovantikNaloxegol Oxalate | 28 | $11,731 |
| Gabapentin | 829 | $11,193 |
| Pregabalin | 549 | $10,827 |
| Morphine Sulfate ErMorphine Sulfate | 218 | $8,529 |
| BelbucaBuprenorphine Hcl | 13 | $8,159 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $7,852 |
| Tizanidine Hcl | 640 | $7,389 |
| Oxycodone Hcl | 456 | $7,190 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $310 | $51,17132 claims |
| AbbVieSavella | $17 | $5,75212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 33 interventional pain medicine providers in Alabama.
Other interventional pain medicine in Montgomery
- Jacob VellaMontgomery$28K
- Bradley KatzMontgomery$12K
- David HerrickMontgomery$9K
- Roger KempMontgomery$74
- Michael KendrickBirmingham$90K
- Bradley WargoMuscle Shoals$41K
- John IronsVestavia$22K
- Richard WebbFoley$18K
- Ryan AlmeidaBirmingham$14K
- Roberto ChangHoover$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.